WO2023002407 - SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
National phase entry is expected:
Publication Number
WO/2023/002407
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056709
International Filing Date
20.07.2022
Title **
[English]
SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
[French]
COMPOSITIONS PHARMACEUTIQUES SOLUBLES COMPRENANT DES SELS DE COMPOSÉ 1, 2, 4-TRIAZINE DISUBSTITUÉ
Applicants **
MINERALYS THERAPEUTICS, INC.
150 N. Radnor Chester Rd, Suite F200
Radnor, Pennsylvania 19087, US
MITSUBISHI TANABE PHARMA CORPORATION
2-10 Dosho-machi, 3-chome, Chuo-ku
Osaka, Hokkaido 541-8505, JP
Inventors
MCKEAN, Robert
c/o Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd, Suite F200
Radnor, Pennsylvania 19087, US
OHASHI, Yoshinori
c/o Mitsubishi Tanabe Corporation
2-10 Dosho-machi, 3-chome, Chuo-ku
Osaka, Hokkaido 541-8505, JP
OZAKI, Fuminori
c/o Mitsubishi Tanabe Pharma Corporation
2-10 Dosho-machi, 3-chome, Chuo-ku
Osaka, Hokkaido 541-8505, JP
OHSHIMA, Hiroki
c/o Mitsubishi Tanabe Pharma Corporation
2-10 Dosho-machi, 3-chome, Chuo-ku
Osaka, Hokkaido 541-8505, JP
NAGATA, Hiroomi
c/o Mitsubishi Tanabe Pharma Corporation
2-10 Dosho-machi, 3-chome, Chuo-ku
Osaka, Hokkaido 541-8505, JP
THIBERT, Roch
150 N. Radnor Chester Road, Suite F200
Radnor, PA 19087, US
VADAS, Elizabeth
150 N. Radnor Chester Road, Suite F200
Radnor, PA 19087, US
Priority Data
63/223,711
20.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2277 | |
| EPO | Filing, Examination | 18494 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10005 |
Total: 31943 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula (I): Formula (I) and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.[French]
L'invention concerne des compositions pharmaceutiques comprenant un sel d'un composé de formule (I) et un ou plusieurs excipients, la composition pharmaceutique évitant l'induction de la dismutation du sel du composé.